Vera Therapeutics, Inc.

VERA Nasdaq SEC CIK 1831828
Follow Vera Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $10.3M
Net income −$93.7M −16.7% vs same quarter last year
EPS, diluted −$1.30 −3.2% vs same quarter last year
Operating cash flow −$99.2M −60.2% vs same quarter last year
Revenue by quarter
$0
$10.3M
Q3 25 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
−$300M−$200M−$100M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$299.6M
FY24−$152.1M
FY23−$96M
FY22−$89.1M
FY21−$32.6M
FY20−$53.4M
FY19-
Free cash flowOperating cash flow minus capital expenditure
−$300M−$200M−$100M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$241.7M
FY24−$135.7M
FY23−$92.2M
FY22−$67.7M
FY21−$23.7M
FY20−$34.9M
FY19-
Returned to shareholdersDividends paid and shares bought back
$0$5K$10K$15KFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearBuybacks
FY25$0
FY24$13K
FY23$0
FY22-
FY21-
FY20-
FY19-